Major Established

विवरण

Escitalopram and ondansetron together carry dual risks: serotonin syndrome and additive QT interval prolongation, making this combination particularly dangerous.

तंत्र

Escitalopram inhibits SERT and prolongs the cardiac QT interval in a dose-dependent manner; ondansetron (5-HT3 antagonist) also prolongs QT and shares serotonergic receptor modulation.

नैदानिक महत्व

FDA issued a drug safety communication (2011) specifically warning against high-dose escitalopram + ondansetron due to fatal arrhythmia risk.

प्रबंधन

Avoid combining when possible; if essential, use the lowest effective doses, obtain baseline and follow-up ECGs, and correct electrolyte abnormalities.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.